Tacrolimus

• UNSPSC Description:

  Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].

• Target Antigen:

  Antibiotic; Autophagy; Bacterial; FKBP; Phosphatase

• Type:

  Natural Products

• Related Pathways:

  Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Immunology/Inflammation;Metabolic Enzyme/Protease

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Tacrolimus.html

• Smiles:

  O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC=C)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@H](O)CC4)[C@H](C)[C@@H](O)CC3=O

• Molecular Weight:

  804.02

• References & Citations:

  [1]Thomson AW, et al. Mode of action of Tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91.|[2]Vogel KR, et al. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. J Inherit Metab Dis. 2016 Nov;39(6):877-886.|[3]Zhu H, et al. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF 1α expression in vivo. Mol Med Rep. 2014 Aug;10(2):585-92.|[4]Okada Y, et al. Tacrolimus ameliorates dextran sulfate sodium-induced colitis in mice: implication of interleukin-1β suppression. Biol Pharm Bull. 2011;34(12):1823-7.|[5]Yuwei He, et al. Drug targeting through platelet membrane-coated nanoparticles for the treatment of rheumatoid arthritis. Nano Res. 30 June 2018.Acs Biomater Sci Eng. 2022 Oct 10.|Acta Pharmacol Sin. 2024 May 17.|Acta Trop. 2020 Dec;212:105708.|Adv Funct Mater. 2023 Sep 15.|Aging Dis. 2023 Jun 6.|Am J Digest Dis. 2015;2(2):95-99.|Am J Transplant. 2022.|Animal Model Exp Med. 2022 Sep 21.|Antiviral Res. 2023 May 2;105618.|Biochim Biophys Acta Gen Subj. 2022 Jun;1866(6):130133.|Biomater Sci. 2020 Oct 7;8(19):5282-5292.|Biomater Sci. 2023 May 2.|Biomaterials. 2021, 120757.|Biomolecules. 2024 Jun 08.|BMC Immunol. 2023 Nov 8;24(1):43.|BMC Pharmacol Toxicol. 2022 Nov 28;23(1):87.|Br J Pharmacol. 2022 Jan 20.|Brain Res. 2019 May 15;1711:68-76.|Cancer Lett. 2024 Apr 11:216841.|Cell Biol Toxicol. 2022 Jun;38(3):487-504.|Cell Commun Signal. 2021 Oct 11;19(1):103.|Cell Mol Biol Lett. 2024 May 14;29(1):72.|Cell Prolif. 2023 Mar 27;e13460.|Cell Rep. 2021 Jul 20;36(3):109404.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Dis Model Mech. 2019 Jan 28;12(1). pii: dmm036830. |Drug Deliv. 2021 Dec;28(1):1759-1768.|Elife. 2023 MAy 19.|Exp Hematol Oncol. 2016 Jul 29;5:22. |FASEB J. 2023 Feb;37(2):e22749.|Food Funct. 2023 Jul 3.|Hepatobiliary Pancreat Dis Int. 2023 Aug 22.|Hepatobiliary Surg Nutr. 2023 Feb 27.|Hong Kong Polytechnic University. 2023 Apr.|Insect Sci. 2023 Oct 12.|Int J Biol Macromol. 2024 Aug 3:134478.|Int J Biol Sci. 2024 Oct 7;20(14):5415-5435.|Int J Mol Sci. 2022 Aug 19;23(16):9376.|Int J Mol Sci. 2024 Feb 21, 25(5), 2503.|Int J Pharm. 2019 Dec 13;575:118951. |Int J Physiol Pathophysiol Pharmacol. 2015 Mar 20;7(1):54-60. |Invest Ophthalmol Vis Sci. 2023 Jan 3;64(1):19.|J Cell Sci. 2019 May 20;132(10):jcs227777.|J Colloid Interface Sci. 5 October 2022.|J Control Release. 2020 Dec 10;328:237-250.|J Extracell Vesicles. 2019 Dec 27;9(1):1709262.|J Neurochem. 2022 Oct 21.|J Pharm Biomed Anal. 2023 Aug 19, 115652.|J Toxicol Sci. 2024;49(8):337-348.|J Vet Med Sci. 2023 Feb 17.|Mater Design. 2023 Nov, 235, 112415.|Mater Today Bio. 2024 Apr 22:101061.|Mediat Inflamm. 2019 Dec 17;2019:4176974.|Mol Med Rep. 2022 May;25(5):160.|Nano Lett. 2019 Jan 9;19(1):124-134.|Nano Res. 11, 6086-6101(2018).|NPJ Regen Med. 2022 Sep 2;7(1):43.|Patent. US20180263995A1.|Patent. US20220087984A1.|Pharmacol Res. 2021, 105382.|Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):e2009539118.|Res Sq. 2024 Aug 13:rs.3.rs-4656461.|Research Square Preprint. 2020 Dec.|Signal Transduct Target Ther. 2023 Nov 1;8(1):417.|Skelet Muscle. 2020 Apr 22;10(1):10.|Theranostics. 2018 Jan 1;8(4):878-893.|Theranostics. 2020 May 16;10(14):6483-6499. |Theranostics. 2021 Mar 5;11(10):5045-5060.|Theranostics. 2022 Jan 16;12(4):1621-1638.|Toxins (Basel). 2019 Jun 18;11(6):349.|Transpl Immunol. 2021 Jun 30;101434.|Ultrasound Med Biol. 2023 Apr 27;S0301-5629(23)00108-4.|Wound Repair Regen. 2023 May 2.|Fundamental Research. 2024 Mar 19.|SSRN. 2023 Oct 31.|Toxics. 2024 Aug 19;12(8):607.|Vaccines. 2024 Sep 29;12(10):1117.

• Shipping Conditions:

  Room Temperature

• CAS Number:

  104987-11-3